A Study of QLS1209 in theTreatment of Patients With Advanced Solid Tumors

Summary

The goal of this clinical trial is to assess the safety and tolerability of QLS1209 alone in patients with eligible advanced solid tumors，determine the maximum tolerated dose (MTD) or maximum drug dose（MAD）of QLS1209, identify a recommended phase 2 dose (RP2D) and preferred schedule, examine preliminary pharmacokinetics (PK) and assess anti-tumor activity.

Timeline

Start

2025-04

Primary completion

2027-04

Completion

2028-04

Drugs

Indications